Trial Profile

A retrospective study assessing cladribine : data from an Italian multiple sclerosis (MS) registry

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 19 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cladribine (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use
Acronyms CLARINET-MS
Sponsors Merck Serono

Most Recent Events

01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology
16 Sep 2019 New trial record
12 Sep 2019 According to an Merck & Co Media release, data from this study will be presented at the 35th Congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS), taking place from 11 to 13 September, 2019, in Stockholm, Sweden.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com